Stock events for Omeros Corp. (OMER)
The past six months have seen several significant events impacting Omeros Corp.'s stock price. Omeros reported its third-quarter financial results, with a net loss of $30.9 million, or $0.47 per share, which was an improvement from the prior year. The FDA extended the PDUFA target action date for narsoplimab to December 26, 2025, to review additional information. Omeros announced the closing of its asset purchase and license agreement with Novo Nordisk for Zaltenibart (OMS906). The FDA approved Omeros's YARTEMLEA (narsoplimab) as the first and only therapy indicated for TA-TMA. Omeros announced the first commercial sales of YARTEMLEA in January 2026. Omeros announced positive results from a primate study in its OncotoX-AML™ drug program. Omeros released its Q4 2025 earnings on March 3, 2026.
Demand Seasonality affecting Omeros Corp.’s stock price
Information specifically detailing demand seasonality for Omeros Corp.'s products and services was not found. Demand is likely driven by disease incidence, diagnosis rates, and treatment adoption rather than typical seasonal consumer patterns.
Overview of Omeros Corp.’s business
Omeros Corporation is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics for various indications, including immunologic disorders, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's business model centers on its proprietary GPCR and complement system programs, addressing diseases with high unmet medical needs. Revenue is generated through product sales, royalty streams, and strategic licensing agreements. Key products include YARTEMLEA (narsoplimab) for TA-TMA, OMS1029 for lectin pathway disorders, Zaltenibart (OMS906) for PNH and C3G, OMS527 for addictions and compulsive disorders, OMIDRIA (royalty streams), OM3 (Oculer NGM) for eye diseases, and the OncotoX-AML™ Drug Program.
OMER’s Geographic footprint
Omeros Corporation is headquartered in Seattle, Washington, United States, and its stock is listed on the NASDAQ exchange. Omeros's stock is also traded on several European exchanges, including Munich, Stuttgart, Frankfurt, Dusseldorf, Hamburg, Berne, and the London Stock Exchange.
OMER Corporate Image Assessment
Omeros Corporation's brand reputation has been significantly influenced by the FDA approval of YARTEMLEA and the strategic licensing agreement for Zaltenibart with Novo Nordisk, generating positive analyst sentiment. However, Omeros is still recognized as a high-volatility biotech entity, with its valuation heavily influenced by clinical trial outcomes and regulatory decisions. The company's financial position, marked by a history of losses and reliance on its pipeline, also contributes to its risk profile.
Ownership
Omeros Corporation's ownership structure includes institutional investors holding approximately 37.84% to 49.73% of the shares, individual insiders holding around 2.84% to 5.11%, and the general public holding between 48.04% and 53%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and UBS Group AG. The largest individual shareholder is CEO Gregory A. Demopulos, owning approximately 2.81% to 3.09% of the company's shares.
